-
1
-
-
33748761925
-
-
Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3):S11 -S25.
-
Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3):S11 -S25.
-
-
-
-
3
-
-
33644938245
-
Immune responses to human papillomavirus
-
Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl 1):S16-S22.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 1
-
-
Stanley, M.1
-
4
-
-
0036364468
-
Immune evasion in human papillomavirus-associated cervical cancer
-
Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002; 2:59-65.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 59-65
-
-
Tindle, R.W.1
-
5
-
-
43049163972
-
Immunobiology of HPV and HPV vaccines
-
This is a comprehensive review that describes the inability of the host to induce an effector immune response against HPV and the various vaccination strategies for HPV
-
Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109 (2 Suppl):S15-S21. This is a comprehensive review that describes the inability of the host to induce an effector immune response against HPV and the various vaccination strategies for HPV.
-
(2008)
Gynecol Oncol
, vol.109
, Issue.2 SUPPL.
-
-
Stanley, M.1
-
6
-
-
0036559896
-
Papillomaviruses and cancer: From basic studies to clinical application
-
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-350.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 342-350
-
-
zur Hausen, H.1
-
7
-
-
0035500930
-
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6
-
Evans M, Borysiewicz LK, Evans AS, et al., Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001; 167:5420-5428.
-
(2001)
J Immunol
, vol.167
, pp. 5420-5428
-
-
Evans, M.1
Borysiewicz, L.K.2
Evans, A.S.3
-
8
-
-
0034572730
-
Regulation of human papillomavirus late gene expression
-
Schwartz S. Regulation of human papillomavirus late gene expression. Ups J Med Sci 2000; 105:171-192.
-
(2000)
Ups J Med Sci
, vol.105
, pp. 171-192
-
-
Schwartz, S.1
-
9
-
-
0345188623
-
Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability
-
Zhou J, Liu WJ, Peng SW, et al., Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999; 73:4972-4982.
-
(1999)
J Virol
, vol.73
, pp. 4972-4982
-
-
Zhou, J.1
Liu, W.J.2
Peng, S.W.3
-
11
-
-
0031902881
-
Cytokine expression in squamous intraepithelial lesions of the uterine cervix: Implications for the generation of local immunosuppression
-
Giannini SL, Al-Saleh W, Piron H, et al., Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998; 113:183-189.
-
(1998)
Clin Exp Immunol
, vol.113
, pp. 183-189
-
-
Giannini, S.L.1
Al-Saleh, W.2
Piron, H.3
-
12
-
-
0037050729
-
Influence of the mucosal epithelium microenvironment on Langerhans cells: Implications for the development of squamous intraepithelial lesions of the cervix
-
Giannini SL, Hubert P, Doyen J, et al., Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97:654-659.
-
(2002)
Int J Cancer
, vol.97
, pp. 654-659
-
-
Giannini, S.L.1
Hubert, P.2
Doyen, J.3
-
13
-
-
0037188431
-
Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo
-
Um SJ, Rhyu JW, Kim EJ, et al., Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 2002; 179:205-212.
-
(2002)
Cancer Lett
, vol.179
, pp. 205-212
-
-
Um, S.J.1
Rhyu, J.W.2
Kim, E.J.3
-
14
-
-
0037105486
-
Human papillomavirus virus-like particles do not activate Langerhans cells: A possible immune escape mechanism used by human papillomaviruses
-
Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169:3242- 3249.
-
(2002)
J Immunol
, vol.169
, pp. 3242-3249
-
-
Fausch, S.C.1
Da Silva, D.M.2
Rudolf, M.P.3
Kast, W.M.4
-
15
-
-
0023720610
-
Epidermal Langerhans cells, dermal dendritic cells, and keratinocytes in viral lesions of skin and mucous membranes: An immunohistochemical study
-
Drijkoningen M, De Wolf-Peeters C, Degreef H, Desmet V. Epidermal Langerhans cells, dermal dendritic cells, and keratinocytes in viral lesions of skin and mucous membranes: an immunohistochemical study. Arch Dermatol Res 1988; 280:220-227.
-
(1988)
Arch Dermatol Res
, vol.280
, pp. 220-227
-
-
Drijkoningen, M.1
De Wolf-Peeters, C.2
Degreef, H.3
Desmet, V.4
-
16
-
-
33745941651
-
Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated premalignant and malignant lesions of the uterine cervix
-
Monnier-Benoit S, Mauny F, Riethmuller D, et al., Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated premalignant and malignant lesions of the uterine cervix. Gynecol Oncol 2006; 102:22-31.
-
(2006)
Gynecol Oncol
, vol.102
, pp. 22-31
-
-
Monnier-Benoit, S.1
Mauny, F.2
Riethmuller, D.3
-
17
-
-
3442888540
-
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6
-
de Jong A, van Poelgeest Ml, van der Hulst JM, et al., Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64:5449-5455.
-
(2004)
Cancer Res
, vol.64
, pp. 5449-5455
-
-
de Jong, A.1
van Poelgeest, M.2
van der Hulst, J.M.3
-
18
-
-
36249028112
-
-
de Boer MA, Jordanova ES, van Poelgeest Ml, et al., Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer 2007; 121:2711 -2715. The study shows that HLA Class I expression status on tumor cells can influence the response to HPV E6/E7 directed immunotherapy.
-
de Boer MA, Jordanova ES, van Poelgeest Ml, et al., Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer 2007; 121:2711 -2715. The study shows that HLA Class I expression status on tumor cells can influence the response to HPV E6/E7 directed immunotherapy.
-
-
-
-
19
-
-
34250838681
-
Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer
-
The study identifies an immunophenotype that is an indicator of dysfunctional T cells in cervical cancer
-
Zehbe I, Kaufmann AM, Schmidt M, et al., Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer. J Immunother 2007; 30:523-532. The study identifies an immunophenotype that is an indicator of dysfunctional T cells in cervical cancer.
-
(2007)
J Immunother
, vol.30
, pp. 523-532
-
-
Zehbe, I.1
Kaufmann, A.M.2
Schmidt, M.3
-
20
-
-
37349068880
-
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element
-
The study provides information on the optimization of cancer immunotherapy for HPV by analyzing T cell interaction with HLA molecules for efficient epitope recognition
-
Piersma SJ, Welters MJ, van der Hulst JM, et al., Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008; 122:486-494. The study provides information on the optimization of cancer immunotherapy for HPV by analyzing T cell interaction with HLA molecules for efficient epitope recognition.
-
(2008)
Int J Cancer
, vol.122
, pp. 486-494
-
-
Piersma, S.J.1
Welters, M.J.2
van der Hulst, J.M.3
-
21
-
-
0031473582
-
Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma
-
Sheu BC, Lin RH, Ho HN, Huang SC. Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 1997; 56 (1-2):39-48.
-
(1997)
Hum Immunol
, vol.56
, Issue.1-2
, pp. 39-48
-
-
Sheu, B.C.1
Lin, R.H.2
Ho, H.N.3
Huang, S.C.4
-
22
-
-
27744566433
-
Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class l-related chain A in advanced human hepatocellular carcinomas
-
Jinushi M, Takehara T, Tatsumi T, et al., Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class l-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43:1013- 1020.
-
(2005)
J Hepatol
, vol.43
, pp. 1013-1020
-
-
Jinushi, M.1
Takehara, T.2
Tatsumi, T.3
-
23
-
-
41449109639
-
Augmented serum level of major histocompatibility complex class l-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions
-
The first report to show high sMICA levels in sera from patients with both cervical cancer and precursor lesions. It may have implication in designing newer therapeutic strategies against HPV
-
Arreygue-Garcia N A, Daneri-Navarro A, del Toro-Arreola A, et al., Augmented serum level of major histocompatibility complex class l-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008; 8:16. The first report to show high sMICA levels in sera from patients with both cervical cancer and precursor lesions. It may have implication in designing newer therapeutic strategies against HPV.
-
(2008)
BMC Cancer
, vol.8
, pp. 16
-
-
Arreygue-Garcia, N.A.1
Daneri-Navarro, A.2
del Toro-Arreola, A.3
-
24
-
-
53449094978
-
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer
-
The study shows that cervical cancer might be a promising target for NK cell-based adoptive immunotherapy
-
Textor S, Durst M, Jansen L, et al., Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123:2343-2353. The study shows that cervical cancer might be a promising target for NK cell-based adoptive immunotherapy.
-
(2008)
Int J Cancer
, vol.123
, pp. 2343-2353
-
-
Textor, S.1
Durst, M.2
Jansen, L.3
-
25
-
-
33747621828
-
-
Wang RF. Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 2006; 28:17-23.
-
Wang RF. Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 2006; 28:17-23.
-
-
-
-
26
-
-
0031939403
-
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
-
Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160:1212-1218.
-
(1998)
J Immunol
, vol.160
, pp. 1212-1218
-
-
Suri-Payer, E.1
Amar, A.Z.2
Thornton, A.M.3
Shevach, E.M.4
-
27
-
-
35348982370
-
Frequencies and role of regulatory T cells in patients with (pre) malignant cervical neoplasia
-
The study shows the involvement of Treg in development of cervical cancer
-
Visser J, Nijman HW, Hoogenboom BN, et al., Frequencies and role of regulatory T cells in patients with (pre) malignant cervical neoplasia. Clin Exp Immunol 2007; 150:199-209. The study shows the involvement of Treg in development of cervical cancer.
-
(2007)
Clin Exp Immunol
, vol.150
, pp. 199-209
-
-
Visser, J.1
Nijman, H.W.2
Hoogenboom, B.N.3
-
28
-
-
34247862322
-
Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer
-
The study describes the involvement of IDO and Treg cells in immune evasion strategies adopted by HPV
-
Nakamura T, Shima T, Saeki A, et al., Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007; 98:874-881. The study describes the involvement of IDO and Treg cells in immune evasion strategies adopted by HPV.
-
(2007)
Cancer Sci
, vol.98
, pp. 874-881
-
-
Nakamura, T.1
Shima, T.2
Saeki, A.3
-
29
-
-
33845991161
-
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth
-
The study introduces a novel role of Nrp-1 in vascular remodeling and anti-vascular endothelial growth factor (VEGF) therapy in reducing tumor growth
-
Pan Q, Chanthery Y, Liang WC, et al., Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11:53-67. The study introduces a novel role of Nrp-1 in vascular remodeling and anti-vascular endothelial growth factor (VEGF) therapy in reducing tumor growth.
-
(2007)
Cancer Cell
, vol.11
, pp. 53-67
-
-
Pan, Q.1
Chanthery, Y.2
Liang, W.C.3
-
30
-
-
0032408496
-
Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins
-
Chen H, He Z, Bagri A, Tessier-Lavigne M. Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron 1998; 21:1283-1290.
-
(1998)
Neuron
, vol.21
, pp. 1283-1290
-
-
Chen, H.1
He, Z.2
Bagri, A.3
Tessier-Lavigne, M.4
-
31
-
-
0037313298
-
-
Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 2003; 3:159-167.
-
Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 2003; 3:159-167.
-
-
-
-
32
-
-
37149048411
-
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer
-
The study describes the important role of semaphorin III receptor Nrp-1 in functional regulation of Treg cells in cervical cancer and elimination of Nrp1, Treg correlated with the reduction of tumor mass
-
Battaglia A, Buzzonetti A, Monego G, et al., Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008; 123:129-138. The study describes the important role of semaphorin III receptor Nrp-1 in functional regulation of Treg cells in cervical cancer and elimination of Nrp1 + Treg correlated with the reduction of tumor mass.
-
(2008)
Immunology
, vol.123
, pp. 129-138
-
-
Battaglia, A.1
Buzzonetti, A.2
Monego, G.3
-
33
-
-
0037404796
-
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix
-
Santin AD, Bellone S, Palmieri M, et al., Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003; 89:271-280.
-
(2003)
Gynecol Oncol
, vol.89
, pp. 271-280
-
-
Santin, A.D.1
Bellone, S.2
Palmieri, M.3
-
34
-
-
33749606658
-
Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions
-
Zehbe I, Schmidt M, Maeurer M, et al., Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions. Zentralbl Gynakol 2006; 128:266-270.
-
(2006)
Zentralbl Gynakol
, vol.128
, pp. 266-270
-
-
Zehbe, I.1
Schmidt, M.2
Maeurer, M.3
-
35
-
-
35948945639
-
Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment
-
The study provides evidence that the suppression of TCR zeta chain is mediated by circulating factor present in sera of cervical cancer patients
-
Shondel SM, Helm CW, Gercel-Taylor C, Taylor DD. Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment. Int J Gynecol Cancer 2007; 17:1278-1282. The study provides evidence that the suppression of TCR zeta chain is mediated by circulating factor present in sera of cervical cancer patients.
-
(2007)
Int J Gynecol Cancer
, vol.17
, pp. 1278-1282
-
-
Shondel, S.M.1
Helm, C.W.2
Gercel-Taylor, C.3
Taylor, D.D.4
-
36
-
-
11244256612
-
In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells
-
Dall P, Herrmann I, Durst B, et al., In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 2005; 54:51-60.
-
(2005)
Cancer Immunol Immunother
, vol.54
, pp. 51-60
-
-
Dall, P.1
Herrmann, I.2
Durst, B.3
-
37
-
-
34548252714
-
-
Smith JF, Brownlow M, Brown M, et al., Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-115. The study demonstrate that Gardasil (r) immunization induces antibodies capable of neutralizing HPV 18 PsV and HPV 45 PsV in vitro, hence, provides an evidence that epitopes on the surface of VLPs may be shared between HPV 18 and HPV 45.
-
Smith JF, Brownlow M, Brown M, et al., Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-115. The study demonstrate that Gardasil (r) immunization induces antibodies capable of neutralizing HPV 18 PsV and HPV 45 PsV in vitro, hence, provides an evidence that epitopes on the surface of VLPs may be shared between HPV 18 and HPV 45.
-
-
-
-
38
-
-
34250850161
-
-
Paavonen J, Jenkins D, Bosch FX, et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161- 2170. The study describes interim analysis of phase III study to assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate vaccine against HPV types 16 and 18 in young women.
-
Paavonen J, Jenkins D, Bosch FX, et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161- 2170. The study describes interim analysis of phase III study to assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate vaccine against HPV types 16 and 18 in young women.
-
-
-
-
39
-
-
33846875433
-
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11
-
The study describes strategy for induction of cross-neutralization antibodies to HPV using L2 epitopes on chimeric VLP vaccine
-
Slupetzky K, Gambhira R, Culp TD, et al., A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007; 25:2001 -2010. The study describes strategy for induction of cross-neutralization antibodies to HPV using L2 epitopes on chimeric VLP vaccine.
-
(2007)
Vaccine
, vol.25
, pp. 2001-2010
-
-
Slupetzky, K.1
Gambhira, R.2
Culp, T.D.3
-
40
-
-
38949200368
-
Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]
-
The study shows efficacy and safety of Cervarix, a prophylactic vaccine for HPV
-
Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008; 68: 359-372. The study shows efficacy and safety of Cervarix, a prophylactic vaccine for HPV.
-
(2008)
Drugs
, vol.68
, pp. 359-372
-
-
Keam, S.J.1
Harper, D.M.2
-
41
-
-
45849125397
-
Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18
-
The review summarizes results of PATRICIA phase III trial for Cervarix vaccine with a specific focus on the results of the interim analysis, and discusses the impact and implications of the findings
-
Frederick PJ, Huh WK. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18. Expert Rev Anticancer Ther 2008; 8:701 -705. The review summarizes results of PATRICIA phase III trial for Cervarix vaccine with a specific focus on the results of the interim analysis, and discusses the impact and implications of the findings.
-
(2008)
Expert Rev Anticancer Ther
, vol.8
, pp. 701-705
-
-
Frederick, P.J.1
Huh, W.K.2
-
42
-
-
33646058566
-
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial
-
Harper DM, Franco EL, Wheeler CM, et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
-
(2006)
Lancet
, vol.367
, pp. 1247-1255
-
-
Harper, D.M.1
Franco, E.L.2
Wheeler, C.M.3
-
43
-
-
42149123438
-
Therapeutic human papillomavirus vaccines: Current clinical trials and future directions
-
This review discusses the future directions of therapeutic HPV vaccine with emphasis on current progress of HPV vaccine clinical trials
-
Hung CF, Ma B, Monie A, et al., Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008; 8: 421-439. This review discusses the future directions of therapeutic HPV vaccine with emphasis on current progress of HPV vaccine clinical trials.
-
(2008)
Expert Opin Biol Ther
, vol.8
, pp. 421-439
-
-
Hung, C.F.1
Ma, B.2
Monie, A.3
-
44
-
-
38049174711
-
DNA vaccines for cervical cancer: From bench to bedside
-
The review describes several strategies for developing therapeutic HPV DNA vaccines for cervical cancer
-
Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39:679-689. The review describes several strategies for developing therapeutic HPV DNA vaccines for cervical cancer.
-
(2007)
Exp Mol Med
, vol.39
, pp. 679-689
-
-
Hung, C.F.1
Monie, A.2
Alvarez, R.D.3
Wu, T.C.4
-
45
-
-
0033814225
-
DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits
-
Han R, Cladel NM, Reed CA, et al., DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 2000; 74:9712-9716.
-
(2000)
J Virol
, vol.74
, pp. 9712-9716
-
-
Han, R.1
Cladel, N.M.2
Reed, C.A.3
-
46
-
-
35848945257
-
-
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell- based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007; 7:1473-1486. This review discusses the different preclinical research strategies for therapeutic vaccines against cervical cancer with emphasis on use of autologous dendritic cell-pulsed HPV16 or 18 E7 as vaccines.
-
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell- based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007; 7:1473-1486. This review discusses the different preclinical research strategies for therapeutic vaccines against cervical cancer with emphasis on use of autologous dendritic cell-pulsed HPV16 or 18 E7 as vaccines.
-
-
-
-
47
-
-
0035139983
-
Danger signals: SOS to the immune system
-
Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114-119.
-
(2001)
Curr Opin Immunol
, vol.13
, pp. 114-119
-
-
Gallucci, S.1
Matzinger, P.2
-
48
-
-
50949115267
-
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
-
The results indicate the potential for combining Treg-cell depletion with anticancer vaccines to enhance tumor antigen-specific immune responses
-
Morse MA, Hobeika AC, Osada T, et al., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112:610-618. The results indicate the potential for combining Treg-cell depletion with anticancer vaccines to enhance tumor antigen-specific immune responses.
-
(2008)
Blood
, vol.112
, pp. 610-618
-
-
Morse, M.A.1
Hobeika, A.C.2
Osada, T.3
-
49
-
-
33744908300
-
-
Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res 2006; 66:4987-4990.
-
Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res 2006; 66:4987-4990.
-
-
-
-
50
-
-
37849046096
-
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
-
This review describes the use of TLR agonists as adjuvants for cancer vaccines. The ability of TLR ligands to induce inflammatory as well as suppressive innate immune responses and to promote the induction of Treg and effector T cells is discussed
-
Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008; 27:168-180. This review describes the use of TLR agonists as adjuvants for cancer vaccines. The ability of TLR ligands to induce inflammatory as well as suppressive innate immune responses and to promote the induction of Treg and effector T cells is discussed.
-
(2008)
Oncogene
, vol.27
, pp. 168-180
-
-
Conroy, H.1
Marshall, N.A.2
Mills, K.H.3
|